Screener
Neurocrine Biosciences NBIX Operating Lease Liability Payments Due
Operating Lease Liability Payments Due at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (dollars in millions) | Operating Leases | Sublease Income |
|---|---|---|
| 2029 | 59.8 | (3.6) |
| 2030 | 60.7 | (3.5) |
| Thereafter | 306.9 | (2.0) |
| Total operating lease payments (sublease income) | 590.2 | $(20.1) |
| Less imputed interest | 126.7 | |
| Total operating lease liabilities | 463.5 | |
| Less current operating lease liabilities included in other current liabilities | 57.3 | |
| Noncurrent operating lease liabilities | $406.2 |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's operating lease liability payments due?
- Neurocrine Biosciences (NBIX) reported operating lease liability payments due of $590.2M in Q1 2026.
- How has Neurocrine Biosciences's operating lease liability payments due changed year-over-year?
- Neurocrine Biosciences's operating lease liability payments due decreased by 8.6% year-over-year, from $645.9M to $590.2M.
- What does operating lease liability payments due mean?
- This represents the total future cash outflows required to satisfy operating lease agreements. It reflects the company's reliance on leased assets rather than owned assets to conduct business operations. Monitoring this helps evaluate the company's operational leverage and fixed cost structure.
Ask your AI about Neurocrine Biosciences's operating lease liability payments due.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude